Is Zevra Therapeutics (ZVRA) Blending Niche Rare-Disease Focus With Mainstream Index Visibility Effectively?
Zevra Therapeutics (ZVRA) was recently added to several Russell indices, increasing its visibility to institutional investors. This comes as the company also published new clinical data for its Niemann-Pick disease type C therapy, MIPLYFFA, in pediatric patients. The article suggests that while the index inclusion and new data are positive, the company's investment narrative still heavily relies on the successful commercialization of MIPLYFFA, effective leadership execution, and upcoming EMA review outcomes.
BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27
BTIG has reiterated its Buy rating on Zevra Therapeutics (ZVRA.US) and maintained a target price of $27. This continued endorsement suggests confidence in the company's future prospects.
(ZVRA) Risk Channels and Responsive Allocation
The article provides an AI-generated analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting strong near and mid-term sentiment that could extend long-term, with no clear price positioning signal or resistance levels above the current price. It offers three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, along with multi-timeframe signal analysis and support/resistance levels.
ZVRA - Zevra Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings information for Zevra Therapeutics Inc. (ZVRA), including its last closing price, market capitalization, key financial ratios, stock performance metrics, and analyst recommendations. It presents a comprehensive overview of the company's financial health, insider and institutional ownership, and valuation.
Enterprise value to revenue forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA
This article is a financial data page from TradingView focusing on Zevra Therapeutics, Inc. (NASDAQ: ZVRA). It provides an overview of the company's financial data, specifically its enterprise value to revenue forward metric. The page includes general market information and links to various TradingView features without providing a detailed analysis.
ZVRA - Zevra Therapeutics Inc Dividends
This article provides detailed financial and stock performance data for Zevra Therapeutics Inc (ZVRA). It lists key metrics such as market capitalization, income, sales, price-to-earnings ratio, various growth rates, and insider/institutional ownership percentages. The data indicates ZVRA has strong profit margins and significant year-over-year growth in EPS and sales.
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell 2000 Value Benchmark
Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell 2000 Value Benchmark, indicating its inclusion in this significant index. This update highlights the company's growing presence in the financial markets and follows other recent inclusions in related Russell indices. Zevra Therapeutics is a commercial-stage rare disease company focusing on therapeutics for conditions like Niemann-Pick disease type C.
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Value Benchmark Index
Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell Microcap Value Benchmark Index. This inclusion is part of a series of recent additions to various Russell indexes, including the Russell 2000 Value Benchmark and Russell 3000 Value Benchmark. The company is a commercial-stage rare disease firm with a late-stage pipeline focused on therapies for rare diseases.
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 3000E Value Benchmark
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 3000E Value Benchmark, effective June 28, 2026. The company, a commercial-stage rare disease firm, also saw its shares added to several other Russell indices, including the Russell 2000 Value and Microcap Value Benchmarks. This inclusion indicates increased market visibility and recognition for Zevra Therapeutics.
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 2000 Value-Defensive Index. This announcement highlights the company's progress and recognition within the financial markets. Zevra Therapeutics is a commercial-stage rare disease company focusing on developing therapeutics for patients with rare diseases.
Price to book forward of Zevra Therapeutics, Inc. – DUS:1GDA
This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating no trades and directing users to more detailed financial data tools.
Price to sales forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA
This article provides financial information for Zevra Therapeutics, Inc. (NASDAQ: ZVRA), specifically focusing on its price to sales forward metric. The content highlights the company's financial overview within the pharmaceuticals sector, as presented on TradingView.
Enterprise value to EBITDA forward of Zevra Therapeutics, Inc. – DUS:1GDA
This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's financial data on the Dusseldorf Stock Exchange as presented on TradingView.
Zevra Therapeutics, Inc. Actuals & Estimates (SWB:1GDA)
This article provides financial actuals and estimates for Zevra Therapeutics, Inc. (SWB:1GDA), including income statement, balance sheet, and cash flow data, alongside analyst forecasts. It details the company's past earnings performance, revenue figures, and upcoming earnings report date, and addresses frequently asked questions about its stock. The article also covers Zevra Therapeutics' stock ticker, analyst price targets, historical high and low prices, and employee count.
Zevra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:1GDA)
This article provides an overview of Zevra Therapeutics, Inc. (TRADEGATE:1GDA) stock, including financial actuals, analyst estimates, and key performance indicators. It covers projected price targets, historical stock prices, upcoming earnings dates, recent earnings and revenue figures, and company statistics like EBITDA and employee count. The stock does not pay dividends and its next earnings report is anticipated on August 18, 2026.
Zevra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ZVRA)
This article provides an overview of Zevra Therapeutics, Inc. (ZVRA) stock performance, financials, and analyst forecasts. It covers recent price changes, historical highs and lows, market capitalization, upcoming earnings reports, and revenue details, along with analyst predictions for future stock prices. The piece also includes frequently asked questions about investing in ZVRA.
1GDA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Zevra Therapeutics, Inc. (1GDA) stock, including analyst price targets, historical highs and lows, and upcoming earnings information. Analysts have given a max estimate of 30.34 EUR and a min estimate of 18.20 EUR for the stock's future price. The company's last reported earnings exceeded estimates, and its next earnings report is due on August 18, 2026.
Form 4 Zevra Therapeutics Inc For: 23 June By Investing.com
This article reports on a Form 4 filing for Zevra Therapeutics Inc., dated June 23. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article provides minimal details beyond the filing's date and the company name.
Zevra Therapeutics chief legal & compliance sells $438,303 in stock
The Chief Legal & Compliance Officer at Zevra Therapeutics, Rahsaan Thompson, sold 34,557 shares of the company's common stock worth $438,303 on June 22, 2026. This sale followed the acquisition of 66,667 shares through restricted stock unit vesting. The transaction was conducted under a Rule 10b5-1 trading plan, with the stock trading at $12.99, up 48% over the last six months, and analysts maintaining positive outlooks following a new patent submission for Miplyffa.
Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise
Zevra Therapeutics' Chief Legal & Compliance Officer, Rahsaan Thompson, exercised 66,667 restricted stock units (RSUs) on June 21, 2026, receiving common shares at $0.00 per share. The following day, he sold 34,557 of these common shares in an open-market transaction at a weighted average price of $12.6835 per share, reducing his direct holdings to 80,235 common shares. This transaction was carried out under a Rule 10b5-1(c) plan adopted on January 8, 2026.
Form 4 Zevra Therapeutics Inc For: 23 June By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4, for Zevra Therapeutics Inc., dated June 23. It notes that ZVRA stock experienced a 2.77% increase and was published on June 23, 2026, at 4:32 p.m. The content itself is terse, largely serving as a placeholder or announcement of the filing rather than a detailed report.
Zevra Therapeutics reports positive MIPLYFFA pediatric data
Zevra Therapeutics reported positive phase 2/3 pediatric substudy data for arimoclomol (MIPLYFFA) in infants with Niemann-Pick disease type C. The study involved five patients and showed the therapy was generally well tolerated with no new safety signals. The pharmacokinetic results were consistent with older pediatric groups when used in combination with miglustat.
Zevra’s infant NPC study finds MIPLYFFA well tolerated
Zevra Therapeutics announced positive data from a phase 2/3 open-label pediatric substudy of MIPLYFFA (arimoclomol) in infants aged 12 to <24 months with Niemann-Pick disease type C (NPC). The study involving five patients found arimoclomol, when added to miglustat, was generally well tolerated with no new safety signals observed, and its pharmacokinetics were consistent with older pediatric groups. These findings, published in "Molecular Genetics and Metabolism Reports," offer preliminary evidence supporting the initiation of MIPLYFFA treatment in very young NPC patients.
Zevra Therapeutics Announces Publication of Positive
Zevra Therapeutics announced the publication of positive data from a pediatric substudy of MIPLYFFA® (arimoclomol) in infants with Niemann-Pick disease type C. The study, published in Molecular Genetics and Metabolism Reports, indicated that MIPLYFFA was well-tolerated in pediatric patients aged 12 to 24 months, with no new safety signals observed. These findings contribute to the growing body of evidence supporting the therapy's use across different age groups and its potential for earlier treatment initiation in this devastating rare disease.
(ZVRA) Movement as an Input in Quant Signal Sets
This article analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA) using AI models, highlighting conflicting sentiment across different time horizons. It provides specific institutional trading strategies, including long, momentum breakout, and short options, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests choppy conditions and compelling upside potential due to the absence of resistance levels above the current price.
Director at Zevra Therapeutics (ZVRA) granted 30,000 stock options
Zevra Therapeutics director Tamara A. Favorito was granted 30,000 stock options with an exercise price of $11.17 on June 4, 2026, as compensation for her board service. The options vest 100% on the earlier of one year from the grant date, the day before the first annual stockholders meeting, or immediately prior to a change in control. These options expire on June 3, 2036, and the transaction was reported via a Form 4 SEC filing.
Zevra Therapeutics (ZVRA) director awarded 30,000 stock options at set price
Zevra Therapeutics (ZVRA) director Alvin Shih was granted 30,000 stock options as compensation for his board service. These options allow him to purchase common shares at an exercise price of $11.17, which was the Nasdaq closing price on June 4, 2026. The options will vest 100% on the earliest of the first anniversary, the day before the first annual stockholders meeting after the grant, or immediately prior to a change in control, and they expire on June 3, 2036.
Zevra Therapeutics (NASDAQ: ZVRA) director gets 30,000 stock options grant
Zevra Therapeutics director Thomas Anderson was granted 30,000 stock options as compensation for his board service. The options have an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026, and vest 100% on the earlier of the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control. These options are set to expire on June 3, 2036.
Zevra Therapeutics (ZVRA) director awarded 30,000 options at $11.17 strike
Zevra Therapeutics director Douglas W. Calder was granted 30,000 stock options as compensation for his board service. The options have an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026, and will vest 100% based on continued service and certain conditions. This grant increases Calder's direct holdings to 30,000 options, in line with Zevra's non-employee director compensation policy.
Zevra Therapeutics (ZVRA) awards director 30,000 stock options
Zevra Therapeutics director Corey Michael Watton was granted 30,000 stock options as compensation for his board service. The options have an exercise price of $11.17 per share, matching the June 4, 2026 Nasdaq closing price, and will expire on June 3, 2036. The options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately prior to a change in control.
Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant
Zevra Therapeutics director Alicia Secor was granted stock options to acquire 30,000 shares of common stock as compensation for her board service. The options have an exercise price of $11.17 per share, equal to the June 4, 2026 closing price, and vest 100% on the earliest of specified service-based dates, expiring on June 3, 2036. This transaction is a compensation award and not a market purchase, aligning director incentives with shareholder interests through equity-based pay.
Zevra Therapeutics Inc (ZVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Zevra Therapeutics Inc (ZVRA) has an earnings forecast score of 8.67, ranking it 13th in the Pharmaceuticals industry. Analysts have an average price target of $24.00 for ZVRA, with forecasts ranging from $18.00 to $26.00, and a "Buy" rating based on 9 analysts. The company's expected revenue for the next quarter is $34.02 million, with an anticipated EPS of $0.09.
Zevra Therapeutics Q2 2025 Earnings Preview
This article provides a preview of Zevra Therapeutics' Q2 2025 earnings report. It highlights expectations for the company's financial performance in the upcoming quarter.
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, M.D., will step down on July 3, 2026, due to personal reasons. Dr. Quartel will continue as a consultant until December 31, 2026, to ensure a smooth transition while the company searches for a new CMO. CEO Neil F. McFarlane praised Dr. Quartel's contributions, including the FDA approval of MIPLYFFA and advancing other pipeline projects, affirming the company's readiness for future milestones.
ZVRA Maintained by Canaccord Genuity -- Price Target Stays at $2
Canaccord Genuity has maintained a 'Buy' rating for Zevra Therapeutics Inc (ZVRA) with a price target of $29.00. GuruFocus's GF Value™ indicates the stock is 43.4% undervalued, and its GF Score™ of 69 suggests good potential for long-term returns, despite a low profitability rank. While insider selling has occurred, the analyst confidence and undervalued status present a compelling case for investors.
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, M.D., will step down on July 3, 2026, due to personal reasons. Dr. Quartel will continue as a consultant through December 31, 2026, to ensure a smooth transition while the company searches for a new CMO. Zevra highlighted Dr. Quartel's contributions to FDA approval of MIPLYFFA and progress on other pipeline programs, confirming it remains on track with regulatory milestones.
Zevra CMO to step down amid EMA review, Phase 3 VEDS trial
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, will step down on July 3, 2026, for personal reasons but will continue as a consultant until December 31, 2026, during the search for a new CMO. The company reassures stakeholders that it remains on track with key regulatory milestones, including an EMA review for arimoclomol in Niemann-Pick disease type C and an ongoing Phase 3 trial for celiprolol in Vascular Ehlers-Danlos Syndrome, with further FDA discussions planned for late 2026. This transition occurs as Zevra focuses on advancing its pipeline and expanding its commercialization efforts.
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, M.D., will step down on July 3, 2026, due to personal reasons. Dr. Quartel will transition to a consulting role through December 31, 2026, as the company searches for a new CMO. The company acknowledged his contributions to FDA approval, commercial launch of MIPLYFFA, advances in celiprolol, and arimoclomol MAA submission, and confirmed it is on track with regulatory milestones and pipeline priorities.
ZVRA Maintains Rating by Maxim Group -- Price Target Raised to $35.00
Maxim Group has maintained a 'Buy' rating for Zevra Therapeutics (ZVRA) and increased its price target from $25.00 to $35.00, suggesting a significant growth
Guggenheim raises Zevra Therapeutics price target on patent extension
Guggenheim has raised its price target for Zevra Therapeutics (NASDAQ:ZVRA) to $29 from $25, maintaining a Buy rating, due to an extended patent protection for its Miplyffa drug until November 2041. This extension significantly prolongs the drug's exclusivity period, enhancing its market potential for the ultra-rare Niemann-Pick disease type C. Other firms like BTIG, Canaccord Genuity, H.C. Wainwright, and Citizens have also adjusted their price targets upwards following this patent news and strong Q1 2026 financial results.
Liquidity Mapping Around (ZVRA) Price Events
This article provides an AI-driven liquidity mapping analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), indicating a potential long-term breakout if strong near and mid-term sentiment persists. It outlines key findings, AI-generated trading strategies for various risk profiles, and multi-timeframe signal analysis, including support and resistance levels. The report highlights compelling upside potential with no remaining resistance above the current price.
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
Shares of Zevra Therapeutics (ZVRA) surged 8% to a nearly five-year high after favorable analyst commentary and a recent patent development for its Miplyffa drug strengthened investor confidence. Analysts from Citizens and Canaccord raised their price targets, citing the potential for extended market exclusivity due to Zevra's application to list the Miplyffa patent in the FDA's Orange Book. This drug, which treats a rare neurological disorder, accounted for over 80% of Zevra's 2025 sales and is a key driver for the stock's positive outlook.
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads
This article highlights several top biotech stock gainers, including Tango Therapeutics (TNGX) which jumped over 50% on positive pancreatic cancer trial data. Alvotech (ALVO) moved closer to FDA approval for its biosimilar to Entyvio, and Zevra Therapeutics (ZVRA) saw gains after strengthening exclusivity for its drug MIPLYFFA. IDEAYA Biosciences (IDYA) also rose as its New Drug Application for Darovasertib is under real-time oncology review.
Zevra moves to list rare disease drug MIPLYFFA in FDA Orange Book
Zevra Therapeutics has submitted U.S. Patent No. 11,707,456 for its rare disease drug MIPLYFFA (arimoclomol) to the FDA for Orange Book listing, extending its exclusivity until November 19, 2041. This move aims to strengthen intellectual property protection for the treatment of Niemann-Pick disease type C. The company also has a pending patent term extension request for another MIPLYFFA patent, which currently expires in 2029, emphasizing its focus on maximizing the drug's long-term value.
Zevra Therapeutics (ZVRA) Files New Patent for Miplyffa
Zevra Therapeutics (ZVRA) has filed a new U.S. Patent, No. 11,707,456, for its medication Miplyffa, aiming for its inclusion in the FDA's Orange Book. This patent offers significant market protection until November 19, 2041, strengthening the company's position in the biotechnology sector. Despite a low profitability rank and recent insider selling, Zevra's strong financial health and promising drug pipeline make it a notable contender in rare disease treatment.
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041
Zevra Therapeutics announced it has submitted a patent for its drug MIPLYFFA to the US FDA's Orange Book, securing exclusivity until 2041. This listing strengthens the product's market position by potentially delaying generic competition. The company, focused on rare disease therapies, saw its shares rise over 9.5% following the announcement.
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
Zevra Therapeutics announced that U.S. Patent No. 11,707,456 for MIPLYFFA has been submitted to the FDA for inclusion in the Orange Book, strengthening the drug's intellectual property protection until November 19, 2041. This move aims to secure long-term value for MIPLYFFA, a therapeutic option for Niemann-Pick disease type C (NPC). The company also has a pending patent term extension for another patent expiring in 2029.
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
Zevra Therapeutics announced the Orange Book listing of U.S. Patent No. 11,707,456 for MIPLYFFA, extending its exclusivity until November 19, 2041. This listing strengthens the intellectual property protection for their therapeutic for Niemann-Pick disease type C (NPC), an ultra-rare neurodegenerative disease. A separate patent term extension application for an earlier patent (No. 11,045,460) with a 2029 expiration is still pending.
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
Zevra Therapeutics announced that its U.S. Patent No. 11,707,456 for MIPLYFFA (arimoclomol) has been submitted to the FDA for listing in the Orange Book, strengthening its intellectual property protection until November 19, 2041. This listing is crucial for preventing generic competitors from entering the market for MIPLYFFA, a treatment for Niemann-Pick disease type C (NPC). The company is also awaiting a decision on a separate patent term extension that currently expires in 2029.
Zevra Therapeutics (NASDAQ: ZVRA) vote keeps classified board structure
Zevra Therapeutics stockholders held their 2026 annual meeting on June 4, 2026, electing two Class II directors and ratifying Ernst & Young LLP as the independent auditor. A proposal to declassify the board failed to pass, as it did not receive the required more-than 66 2/3% of outstanding shares for approval, thus maintaining the current classified board structure. This outcome means that only a portion of the board directors will be up for election each year, providing resistance against hostile takeovers but potentially slowing strategic changes.
